Increasing participant diversity in AD research: Plans for digital screening, blood testing, and a community‐engaged approach in the Alzheimer's Disease Neuroimaging Initiative 4. Issue 1 (9th October 2022)

• Record Type: Journal Article
• Authors: Weiner, Michael W.; Veitch, Dallas P.; Miller, Melanie J.; Aisen, Paul S.; Albala, Bruce; Beckett, Laurel A.; Green, Robert C.; Harvey, Danielle; Jack, Clifford R.; Jagust, William; Landau, Susan M.; Morris, John C.; Nosheny, Rachel; Okonkwo, Ozioma C.; Perrin, Richard J.; Petersen, Ronald C.; Rivera‐Mindt, Monica; Saykin, Andrew J.; Shaw, Leslie M; Toga, Arthur W.; Tosun, Duygu; Trojanowski, John Q.
• Is Part Of: Alzheimer's & dementia. Volume 19:Issue 1(2023)
• Page Start: 307
• Page End: 317
• Publication Date: 2022-10-09
• Subjects: Alzheimer's disease -- amyloid -- cerebrovascular disease -- digital biomarkers -- generalizability -- mild cognitive impairment -- plasma biomarkers -- tau -- underrepresented populations; Alzheimer's disease -- Periodicals; Alzheimer Disease -- Periodicals; Dementia -- Periodicals; Démence; Maladie d'Alzheimer; Périodique électronique (Descripteur de forme); Ressource Internet (Descripteur de forme); 616.83
• DOI: 10.1002/alz.12797
• Languages: English
• ISSNs: 1552-5260

Abstract

Abstract: Introduction: The Alzheimer's Disease Neuroimaging Initiative (ADNI) aims to validate biomarkers for Alzheimer's disease (AD) clinical trials. To improve generalizability, ADNI4 aims to enroll 50‐60% of its new participants from underrepresented populations (URPs) using new biofluid and digital technologies. ADNI4 has received funding from the National Institute on Aging beginning September 2022. Methods: ADNI4 will recruit URPs using community‐engaged approaches. An online portal will screen 20, 000 participants, 4000 of whom (50‐60% URPs) will be tested for plasma biomarkers and APOE . From this, 500 new participants will undergo in‐clinic assessment joining 500 ADNI3 rollover participants. Remaining participants (∼3500) will undergo longitudinal plasma and digital cognitive testing. ADNI4 will add MRI sequences and new PET tracers. Project 1 will optimize biomarkers in AD clinical trials. Results and Discussion: ADNI4 will improve generalizability of results, use remote digital and blood screening, and continue providing longitudinal clinical, biomarker, and autopsy data to investigators.